IDF-11774 is primarily investigated for its potential in cancer therapy. It functions as an inhibitor of hypoxia-inducible factor 1 (HIF-1), a key regulator in tumor growth and survival under low oxygen conditions. By targeting HIF-1, IDF-11774 disrupts the adaptation of cancer cells to hypoxic environments, which are common in solid tumors. This action can inhibit angiogenesis, reduce tumor metabolism, and enhance the effectiveness of other cancer treatments like chemotherapy and radiation. Its application is particularly promising in treating cancers that are highly dependent on hypoxia-related pathways, such as certain types of breast, prostate, and pancreatic cancers. Ongoing research aims to optimize its efficacy and explore its use in combination therapies.